Polaris Program / John Kraus The 43rd International Space Development Conference Will Be Held in Orlando on June 19 ...

The US Food and Drug Administration (FDA) has accepted the resubmission of the Biologics License Application (BLA) for ...

New Chair brings more than three decades of life sciences industry experience, with a successful track record as a biotech company board ...

NX-5948 assigned the nonproprietary name "bexobrutideg"U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

NX-5948 assigned the nonproprietary name “bexobrutideg”U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemiaAchieved $7M in milestones and a $15M ...

Newleos Therapeutics, Inc., a clinical-stage neuroscience company co-founded by Longwood Fund and seasoned leaders in CNS drug development, today announced the expansion of its leadership team with ...

A new company has entered the drug discovery space with what it calls a “chemistry-first” platform. Colorado-based Cime ...

Liquidia's collaboration with Sandoz and development of new products like L606 show promise. Learn why LQDA stock is a Hold.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

As the FDA’s top biologics official, Peter Marks oversaw regulation of cell and gene therapies. The departure of Marks and ...

Seven business leaders with ties to the D.C. area have joined Forbes list of global billionaires for the first time ever. The ...